Friday, October 16, 2026

Financial Markets

2 articles

Figure Technology's AAA Blockchain Rating Opens a New Era for Global Tokenized Debt Markets

Figure Technology's AAA Blockchain Rating Opens a New Era for Global Tokenized Debt Markets

A US fintech has secured the first-ever AAA credit rating for a blockchain-based securitization product, a milestone that analysts say could accelerate the adoption of tokenized debt instruments across international capital markets. The achievement by Figure Technology Solutions removes a key fiduciary barrier that has long kept institutional investors worldwide on the sidelines of real-world asset tokenization. Industry observers expect the breakthrough to trigger a wave of similar filings from

ViaNews Editorial Team•
First AAA-Rated Blockchain Securitization Marks a Global Turning Point for Institutional DeFi

First AAA-Rated Blockchain Securitization Marks a Global Turning Point for Institutional DeFi

A landmark AAA credit rating on a blockchain-based loan securitization by US lender Figure Technology Solutions signals that global institutional capital — long barred from decentralised finance by the absence of investment-grade ratings — may finally be ready to enter the space. The development carries implications far beyond Wall Street, touching sovereign wealth funds, European insurance regulators, and emerging market fintech ecosystems seeking credible capital market infrastructure.

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com